Drug-resistant variants of Escherichia coli thymidylate synthase: Effects of substitutions at Pro-254

Molecular Pharmacology

Volumn 57, Issue 2, 2000, Pages 359-366

  Fantz, Corinne ^a   Shaw, David ^a   Jennings, William ^a   Forsthoefel, Antonia ^a   Kitchens, Maria ^a   Phan, Jason ^a   Minor, Wladek ^c   Lebioda, Lukasz ^a   Berger, Franklin G ^a   Spencer, H Trent ^a,b  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b South Carolina Cancer Center   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME VARIANT; FLOXURIDINE; FLUOROPYRIMIDINE DERIVATIVE; FOLIC ACID ANTAGONIST; METHYLENETETRAHYDROFOLIC ACID; PROLINE; RALTITREXED; THYMIDYLATE SYNTHASE;

AMINO ACID SUBSTITUTION; ARTICLE; BONE MARROW SUPPRESSION; CANCER SUSCEPTIBILITY; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DRUG MECHANISM; DRUG RESISTANCE; ESCHERICHIA COLI; GENE THERAPY; HUMAN; HUMAN CELL; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN VARIANT;

AMINO ACID SUBSTITUTION; CRYSTALLOGRAPHY, X-RAY; DEOXYURACIL NUCLEOTIDES; DRUG RESISTANCE; DRUG RESISTANCE, MICROBIAL; ENZYME INHIBITORS; ESCHERICHIA COLI; FLUORODEOXYURIDYLATE; FOLIC ACID ANTAGONISTS; HUMANS; KINETICS; MUTATION; PROLINE; PROTEIN CONFORMATION; QUINAZOLINES; TETRAHYDROFOLATES; THYMIDYLATE SYNTHASE; TRANSFECTION;

EID: 0033950404     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Allay J, Persons D, Galipeau J, Riberdy J, Ashmun R, Blakley R and Sorrentino B (1998) In vivo selection of retrovirally transduced hematopoietic stem cells. Nat Med 4:1136-1143.
2. Brunger AT, Adams PD, Clore GM, Delano WL. Gros P, Grosse-Kunstleve RW, Jiang J-S, Kuszewski J, Nilges M, Pannu NS, Read RJ, Rice LM, Simonson T and Warren GL (1998) Crystallographic & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr Sect D Biol Crystallogr 54:905-921.
3. Carreras CW and Santi DV (1995) The catalytic mechanism and structure of thymidylate synthase. Annu Rev Biochem 64:721-762.
4. Collaborative Computational Project, Number 4 (1994) The CCP4 suite: Programs for protein crystallography. Acta Crystallogr Sect D Biol Crystallogr 50:760-763.
5. Davisson VJ, Sirawaraporn W and Santi DV (1989) Expression of human thymidylate synthase in Escherichia coli. J Biol Chem 264:9145-9148.
6. Deisseroth AB, Kavanagh J and Champlin R (1996) Use of safety-modified retroviruses to introduce chemotherapy resistance sequences into normal hematopoietic cell for chemoprotection during the therapy of ovarian cancer: A pilot trial. Hum Gene Ther 7:401-416.
7. Fantz C, Shaw D, Moore J and Spencer H (1998) Retroviral coexpression of thymidylate synthase and dihydrofolate reductase confers fluoropyrimidine and antifolate resistance. Biochem Biophys Res Comm 243:6-12.
8. Flasshove M, Banerjee D, Mineishi S, Li M-X, Bertino JR and Moore MAS (1995) Ex vivo expansion and selection of human CD34 peripheral blood progenitor cells after introduction of a mutated dihydrofolate reductase cDNA via retroviral gene transfer. Blood 85:566-574.
9. Hesdorffer C, Antman K, Bank A, Fetell M, Mears G and Begg M (1994) Human MDR gene transfer in patients with advanced cancer. Hum Gene Ther 5:1151-1160.
10. Ho S, Hunt H, Horton R, Pullen J and Pease L (1989) Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 20:51-59
11. Hock RA and Miller AD (1986) Retrovirus mediated transfer and expression of drug resistance genes in human haematopoietic progenitor cells. Nature (Lond) 320: 275-277.
12. Hyatt D, Maley F and Monfort W (1997) Use of strain in a stereo specific catalytic mechanism crystal structures of Escherichia coli thymidylate synthase bound to FdUMP and methylenetetrahydrofolate. Biochemistry 36:4585-4594.
13. Jackson RC, Johnston A, Shetty B, Varney M and Webber S (1993) Molecular design of thymidylate synthase inhibitors. Proc Am Assoc Cancer Res 34:566.
14. Kitchens M, Forsthoefel A, Barbour K, Spencer T and Berger F (1999) Mechanisms of acquired resistance to thymidylate synthase inhibitors: The role of enzyme stability. Mol Pharmacol 55:1063-1070.
15. Koc O, Allay J, Lee K, Davis B, Reese J and Gerson S (1996) Transfer of drug resistance genes into hematopoietic progenitors to improve chemotherapy tolerance. Semin Oncol 23:46-65.
16. Landis D and Loeb L (1998) Random sequence mutagenesis and resistance to 5-fluorouridine in human thymidylate synthase. J Biol Chem 273:25809-25817.
17. Matthews D, Appelt K, Oatley S and Xuong N (1990) Escherichia coli thymidylate synthase containing bound 5-fluoro-2′-deoxyuridylate and 10-propargyl-5,8-dideazafolate. J Mol Biol 214:923-936.
18. May C, James RI, Gunther R and McIvor RS (1996) Methotrexate dose-escalation studies in transgenic mice and marrow transplant recipients expressing drug-resistant dihydrofolate reductase activity. J Pharmacol Exp Ther 278:1444-1451.
19. Montfort W, Perry K, Fauman E, Finer-Moore J, Maley G, Hardy L, Maley F and Stroud R (1990) Structure, multiple site binding, and segmental accommodation in thymidylate synthase on binding dUMP and an anti-folate. Biochemistry 29:6964-6977.
20. O'Shaughnessy JA, Cowan KH, Nienhuis AW, McDonagh KG, Sorrentino BP, Dunbar CE, Chiang Y, Wilson W, Goldspiel B, Kohler D, Cottier-Fox M, Leitman S, Gottesman MM, Pastan I, Denicoff RN, Noone M and Gress R (1994) Clinical Protocol: Retroviral mediated transfer of the human multidrug resistance gene into hematopoietic stem cells during autologous transplantation after intensive chemotherapy for metastatic breast cancer. Hum Gene Ther 5:891-911.
21. Otwinowski Z and Minor W (1997) Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 307:276-326.
22. Perry K, Carreras C, Chang L, Santi D and Stroud R (1993) Structures of thymidylate synthase with a C-terminal deletion: Role of the C-terminus in alignment of 2′-deoxyuridine 5′-monophosphate and 5,10-methylenetetrahydrofolate. Biochemistry 32:7116-7125.
23. Reilly RT, Barbour KW, Dunlap RB and Berger FG (1995) Biphasic binding of 5-fluoro-2′-deoxyuridylate to human thymidylate synthase. Mol Pharmacol 48:72-79.
24. Sack JS and Quiocho FA (1997) CHAIN: A crystallographic modeling program. Methods Enzymol 277:158-173.
25. Sorrentino BP, Brandt SJ, Bodine D, Gottesman M, Pastan I, Cline A and Nienhuis AW (1992) Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR. Science (Wash DC) 257:99-103.
26. Spencer HT, Sleep SH, Rehg JE, Blakley RL and Sorrentino BP (1996) A gene transfer strategy for making bone marrow cells resistant to trimetrexate. Blood 87:2579-2587.
27. Spencer HT, Villafranca JE and Appleman JR (1997) Kinetic scheme for thymidylate synthase form Escherichia coli: Determination from measurements of ligand binding, primary and secondary isotopes effects, and presteady-state catalysis. Biochemistry 36:4212-4222.
28. Tong Y, Liu-Chen X, Ercikan-Abali E, Capiaux G, Zhao S, Banergee D and Bertino J (1998a) Isolation and characterization of thymitaq (AG337) and 5-fluoro-2-deoxyuridylate-resistant mutants of human thymidylate synthase from ethylmethanesulfonate-exposed human sarcoma HT1080 cells. J Biol Chem 273:11611-11618.
29. Tong Y, Liu-Chen X, Ercikan-Abali E, Zhao S, Banergee D, Maley F and Bertino J (1998b) Probing the folate-binding site of human thymidylate synthase by site-directed mutagenesis. J Biol Chem 273:31209-31214.
30. Touroutoglou N and Pazdur R (1996) Thymidylate synthase inhibitors. Clin Cancer Res 2:227-243.